[20210219]IN11609_2019冠状病毒疾病疫苗：管理资金.pdf

CRS INSIGHT Prepared for Members and Committees of Congress INSIGHTINSIGHTi i COVID-19 Vaccine: Financing for Its Administration February 19, 2021 A U.S. COVID-19 vaccination campaign is underway. For this effort, all vaccines and some supplies for their administration to patients have been purchased by the federal government, with appropriations provided for this purpose. These are available at no cost to providers and patients. When the vaccine delivery approach allows for individual patient transactions, providers may seek reimbursement from available payers for their costs to administer the vaccines, including the costs of their time, vaccine storage, recordkeeping, and additional supplies. In general, by law and regulation, patients should not be charged for the COVID-19 vaccine or the costs of its administration during the campaign. There may be exceptions when the vaccine is administered during a visit in which other servicessuch as a check-up for a chronic conditionare also furnished, and a visit fee unrelated to vaccine administration may be billed. This Insight explores the provision of COVID-19 vaccines and payment for their administration, where applicable, from the per